Montelair (Montelukast)

Montelukast, the active ingredient in Montelair, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to treat asthma, allergic rhinitis and to prevent exercise‑induced bronchoconstriction in adults and children. GNH USA supplies Montelair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelair belongs to the leukotriene receptor antagonist class and is used in respiratory and allergic conditions. - Asthma: provides maintenance therapy that reduces airway inflammation and frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itching caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: prevents bronchospasm that can occur during physical activity.

Montelair is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Nausea - Dizziness - Fatigue - Cough

Serious or Rare Side Effects: - Angioedema or severe allergic reactions - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Eosinophilic granulomatosis with polyangiitis (Churg‑Strauss syndrome) - Hepatic injury - Mood changes, including depression or suicidal thoughts - Severe bronchospasm despite therapy

Before initiating therapy, consider the following precautions. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown excretion; weigh benefits against possible infant exposure. - Renal impairment: dose adjustment may be required in severe cases. - Concomitant medications: review for potential interactions that could alter efficacy. - Pediatric use: approved for specific age groups; follow local labeling. Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Montelair may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Ritonavir: can increase montelukast plasma concentrations. - Phenobarbital: may markedly reduce montelukast effectiveness. - Carbamazepine: may lower systemic exposure to montelukast.

Moderate Interactions (Monitor Closely): - Fluconazole: may raise montelukast levels; observe for side effects. - Warfarin: potential alteration of INR; monitor coagulation parameters.